



## ASX and Media Release

# Viralytics' Patent Coverage Expanded

## Notice of European patent allowance

**7 August 2013, Sydney, Australia:** Viralytics Limited (ASX:VLA, OTCQX:VRACY) has expanded the company's patent portfolio after a notice of allowance of an additional patent by the European Patent Office.

Viralytics' lead product CAVATAK™ is already protected with a portfolio of patents across major markets and these include a European Patent for the Coxsackie A group viruses (including CAVATAK™).

The additional patent in Europe broadens the scope of the core patent covering Coxsackie A viruses to now include the much wider family of all Picornaviruses that bind to intercellular adhesion molecule-1 (ICAM-1) in the process of killing cancer cells.

A notice of allowance indicates the intention of the European Patent Office to grant a patent after an administrative process is completed.

Dr Malcolm McColl, Viralytics Chief Executive Officer said, "the grant of this patent will significantly strengthen Viralytics' intellectual property portfolio in Europe to cover the broad use of all Picornaviruses, including CAVATAK™, that destroy cancerous cells following binding to cell surface expressed ICAM-1. The European Union is the world's second largest pharmaceutical market and broadening our patent portfolio in this market is a very valuable additional asset for the company."

**Enquiries:**  
**Dr Malcolm McColl**  
**02 9988 4000**

**Rudi Michelson**  
**Monsoon Communications**  
**03 9620 3333**

---

### About Viralytics Ltd:

Viralytics is developing oncolytic virotherapy treatments for a range of cancers. Viralytics' lead product, CAVATAK™, is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21). CVA21 binds to specific 'receptor' proteins highly expressed on multiple cancer types including, but not limited to: melanoma; prostate, lung, breast and bladder cancers; and multiple myeloma. CAVATAK™ acts to kill both local and metastatic cancer cells, by direct cytolysis and a possible immune response. The preferential targeting of cancer rather than healthy cells provides the potential for low toxicity in the patient. The company is actively enrolling a phase II clinical trial, of intratumourally administered CAVATAK™ in the treatment of Late stage Melanoma (the CALM study), at multiple prestigious cancer clinics in the US. Viralytics plans to commence a Phase I/II trial of CAVATAK™ being delivered systemically (intravenously). This trial referred to as the STORM (Systemic Treatment Of Resistant Malignancies) study will be undertaken in patients with melanoma, prostate, lung or metastatic bladder cancers. The second stage of the STORM trial will include combination treatments with

For personal use only



existing chemotherapies in one of the above cancer types. Subject to regulatory approval the STORM trial will commence at three prominent UK sites later in 2013.

Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics' ADRs also trade under the symbol "VRACY" on the US OTCQX International market.

For personal use only